FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* KEISER DAVID W							2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC									elationship o eck all applic C Directo	*			
(Last) (First) (Middle)					- AI	ALXN]										Officer below)	(give title		Other (specify below)	
C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE						Date 0 /30/2		iest Trans	sactio	ion (Mon	nth/D	oay/Year)		President & COO						
(Charan)						4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable ine)				
(Street) CHESHIRE CT 06410																Form fi	ed by One Reporting Person		n	
(City) (State) (Zip)					-											Form filed by More than One Reporting Person				ting
		Tab	le I - Nor	n-Deriv	vative	e Se	curit	ties Ac	qui	ired, D)isp	osed o	f, or	Bene	eficiall	y Owned				
Date					e nth/Day/Year) i			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transact Code (In 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				5. Amou Securitie Beneficia Owned F	s ally following	Form (D) o	n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									-	Code	v	Amount	((A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)
Common Stock, par value \$.0001 per share 07/30/						8				М		10,00	0	A	\$21	119	9,682		D	
Common Stock, par value \$.0001 per share 07/30/						8				S		10,000)(1)	D	\$90	109	9,682		D	
		-	Гable II -									sed of, onvertil				Owned		,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution I if any (Month/Day	Date,		ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Date Exe piration I pnth/Day	Date	of Securities		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	te ercisable		xpiration ate	Title	O N	Amount or Number of Shares					
Option to Purchase Common Stock	\$21	07/30/2008			М			10,000	06/	/14/2001	0	6/14/2011	Stoc par va \$.00	ck, alue 1 01	10,000	\$0	17,970)	D	

Explanation of Responses:

1. The sales reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1 (c) (1) of the Securities Exchange Act.

<u>/s/ David Keiser</u> <u>08/01/2008</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.